



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

25 April 2014
EMA/CHMP/225802/2014

CHMP List of questions

To be addressed by the marketing authorisation holder(s) for adrenaline auto-injectors (AAIs)

Article 31 of Directive 2001/83/EC

Procedure number: EMEA/H/A-31/1398

Active substance: adrenaline (epinephrine)



The marketing authorisation holders (MAHs) for adrenaline auto-injectors (AAIs) are requested to provide the following:

Question 1

The MAHs are requested to submit the relevant sections (i.e. text concerning the posology, administration instructions and precautions, pharmacokinetics) of the currently approved Summaries of Product Characteristics (SmPCs) and Package Leaflets (PLs) for their adrenaline auto-injector products.

Question 2

Variability in skin-to-muscle depth, needle length and the device mechanism itself are important factors which determine whether the route of delivery is intra-muscular (IM) or subcutaneous (SC). What is the available supporting non-clinical and clinical evidence to describe and justify the tolerance limits for these parameters to ensure IM administration that better informs instruction for use? Are other parameters important? Reliance on non-clinical data should be supported by justification that these models are relevant to the clinical setting.

Question 3

To address any deficiencies in the current evidence base and to generate a more reliable evidence base that better informs instruction for use, the MAHs are requested to discuss the possibility of providing clinical evidence (such as penetration/absorption studies using stable isotopes or other traceable markers and suitable imaging) in a broad range of phenotypes, on the site of delivery of adrenaline solution when administered with their respective auto-injector devices in accordance with the instructions for use.